Truncated Acid-Alpha Glucosidase for Systemic Pompe Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Pompe disease, such as enzyme-replacement therapy (ERT) and gene therapy, are limited by frequent infusions, immunogenicity, and inadequate biodistribution, failing to provide comprehensive correction of glycogen accumulation in tissues.
Innovation Solution
Development of truncated GAA polypeptides with specific deletions at the N-terminal end, optionally combined with signal peptides, to enhance secretion and induce immunological tolerance, using optimized nucleic acid constructs and vectors for widespread tissue expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme-replacement therapy (ERT) is used to treat Pompe disease, then glycogen accumulation in tissues is corrected, but frequent infusions are required and immunogenicity develops
Solution Approach 1:
The patent introduces a liver-specific promoter (e.g., AAT promoter) to drive GAA expression in the liver before systemic distribution. This preliminary action in the liver creates a reservoir of GAA that is then secreted into the bloodstream, providing sustained therapeutic levels without frequent infusions. The liver acts as a bioreactor that continuously produces and releases GAA systemically.
2Reliability
If enzyme-replacement therapy (ERT) is used to treat Pompe disease, then glycogen accumulation in tissues is corrected, but inhibitor antibodies are developed against recombinant hGAA
Solution Approach 1:
The patent uses the liver as an intermediary organ to produce and secrete GAA. By expressing GAA in liver cells (hepatocytes) rather than administering it directly, the therapy leverages the liver's natural secretory pathways to deliver GAA systemically. This intermediary approach reduces immunogenicity compared to direct peripheral vein delivery of recombinant hGAA.
3Reliability
If muscle-directed gene transfer is used to treat GSD-II, then genetic defect is corrected, but expression is more immunogenic compared with other tissues
Solution Approach 1:
Instead of the conventional approach of directly targeting muscle tissue with gene therapy, the patent inverts the strategy by first expressing GAA in the liver (a less immunogenic tissue) and then relying on systemic secretion to deliver GAA to muscle and other target tissues. This reverse approach reduces immunogenicity while still achieving therapeutic correction in muscle.
4Ease of operation
If chimeric GAA polypeptide with signal peptide is used, then targeting to secretory pathway is enhanced, but tissue distribution is not entirely satisfactory
Solution Approach 1:
The patent optimizes the coding sequence of GAA for enhanced expression in liver cells and combines it with a liver-specific promoter. This parameter change (codon optimization for liver expression) maximizes GAA production in the liver, which then secretes GAA systemically to achieve broad tissue distribution including muscle, heart, and other glycogen-storing tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The truncated GAA polypeptides demonstrate improved secretion and reduced immunogenicity, effectively correcting glycogen accumulation in various tissues and inducing tolerance, thereby providing long-term therapeutic efficacy.
Implementation Method 1
GAA is an exo-1,4 and 1,6-α-glucosidase that hydrolyzes glycogen to glucose in the lysosome
Data Source
AI summary
The present invention relates to variants of acid-alpha glucosidase and uses thereof.